German enzyme SME specializing in enzymatic plastic recycling, bio-packaging, and bioprocess support for vaccine development across EU consortia.
ASA Spezialenzyme is a German SME specializing in the development and production of specialty enzymes for industrial and biotech applications. Their core capability is applying enzymatic processes to two distinct domains: breaking down plastics (PET, polyolefins, multi-layer packaging) for circular economy recycling, and supporting GMP-grade bioproduction for vaccine and therapeutic development. They serve as a technical enzyme supplier and process partner within large European research consortia, contributing enzyme expertise to projects ranging from bio-urban waste recovery to influenza and Chagas disease vaccine development.
Core contributor to ENZYCLE (PET/polyolefin depolymerization), RECOVER (plastic biodegradation), BioSupPack (enzymatic recycling of bio-packaging), and SCALIBUR (bio-urban waste recovery).
Active in SCALIBUR (bioplastics from waste), BioSupPack (PHA/PHB rigid packaging with enzymatic recycling), and RECOVER (chitin-based biopolymers).
Contributed to CRUZIVAX (GMP production for Chagas vaccine) and INCENTIVE (next-generation influenza vaccine), likely providing enzyme/bioprocess expertise for antigen production.
SCALIBUR focused on recovering proteins, energy, and bioplastics from urban bio-waste; RECOVER addressed agri-food waste plastics biodegradation.
ASA Spezialenzyme entered H2020 in 2018 with a dual focus: bio-waste valorization (SCALIBUR) and vaccine bioprocessing (CRUZIVAX with GMP production for Chagas). From 2020 onward, their portfolio shifted heavily toward enzymatic plastic recycling — three of their four most recent projects (ENZYCLE, RECOVER, BioSupPack) center on using enzymes to break down or recycle different plastic types. The health thread continued but narrowed to immune-related work (INCENTIVE). The clear trend is consolidation around enzymatic solutions for the circular plastics economy.
ASA is doubling down on enzymatic plastic degradation and bio-packaging recycling — expect them to seek partnerships in circular economy, waste management, and sustainable packaging going forward.
ASA participates exclusively as a partner, never as coordinator, which is typical for a specialist SME contributing deep technical capability to larger consortia. With 93 unique partners across 19 countries in just 6 projects, they consistently join large, multi-national consortia (averaging 15+ partners per project). This suggests they are a trusted enzyme specialist that gets invited into ambitious collaborative projects rather than building small bilateral partnerships.
Extensive network of 93 unique partners across 19 countries built through 6 large consortia, indicating broad European reach and cross-sector connections spanning environmental technology, food science, and health research institutions.
ASA occupies a rare niche as an enzyme SME that bridges industrial biotech and health biotech within EU research. While most enzyme companies focus on either industrial applications or pharma, ASA contributes enzymatic expertise to plastic recycling, bio-packaging, AND vaccine production — a versatility that makes them valuable to consortium builders in multiple sectors. Their Wolfenbüttel base places them in Germany's biotech corridor, and their consistent participation in RIA and IA projects shows they can operate at both research and near-market demonstration scales.
